ライフサイエンスコーパス: biologic marker

1 entified using a combination of clinical and biologic markers.

2 the scoring systems through addition of new biologic markers.

3 cal activity indices in CD and with numerous biologic markers.

4 ctious complications, and prognostic role of biologic markers.

5 ed with specific clinical manifestations and biologic markers and may be a useful addition to the bio

6 We recommend that biologic markers and response to treatment be incorporat

7 a decrease in profibrotic and proangiogenic biologic markers, and upregulation of lung CXCL11 mRNA a

8 Many biologic markers are associated with poor prognosis in c

9 Biologic markers are increasingly being used to help wit

10 Biologic markers are increasingly being used to help wit

11 tion-based data directly comparing these two biologic markers are not available.

12 rapy and tested microbiologic, clinical, and biologic markers as prognostic indicators for clinical s

13 We recommend that biologic markers be incorporated into revised versions o

14 We recommend that treatment response and biologic markers be incorporated into the American Joint

15 A number of clinical factors and biologic markers can be used to differentiate groups of

16 Functional studies suggest that biologic markers could be useful in defining the phenoty

17 led to more pronounced beneficial effects in biologic marker expressions in pulmonary acute respirato

18 uggest that toenail samples provide a useful biologic marker for quantifying low-level arsenic exposu

19 inducible hsp70 in the model could provide a biologic marker for the prediction of clinical acute and

20 othelial progenitor cells may be a surrogate biologic marker for vascular function and cumulative car

21 The identification of biologic markers for disease outcome in hematopoietic ma

22 tments, and the advent of valid and reliable biologic markers hold promise in the coming decade for d

23 We suggest that the use of such surrogate biologic markers in conjunction with F-cell numbers may

24 use of a combination of clinical factors and biologic markers is a promising strategy that needs to b

25 ntal diagnostic value over other imaging and biologic markers makes them easier to implement by other

26 A biologic marker of collagen synthesis in the lung may be

27 evaluate toenail arsenic concentrations as a biologic marker of drinking water arsenic exposure.

28 by PTSD is corroborated using an independent biologic marker of immune response to infection, CMV-a t

29 Plasma carotenoids are a biologic marker of intake of vegetables and fruit, so th

30 nst recombinant tick calreticulin (rTC) as a biologic marker of tick exposure.

31 ecipients' telomere length is an independent biologic marker of TRM after HSCT.

32 was to review known clinical predictors and biologic markers of adverse clinical outcomes in acute l

33 ar attention as persons who have accumulated biologic markers of disease.

34 dy adjusted for C-reactive protein (CRP) and biologic markers of inflammation such as CRP, interleuki

35 these to fluorodeoxyglucose (FDG) uptake and biologic markers of inflammation.

36 Several biologic markers of mortality have also been identified

37 on and diminished PMN apoptosis may serve as biologic markers of myocardial failure.

38 t appropriate statistical methods to analyze biologic markers of stress, such as salivary cortisol, r

39 lude absence of gas exchange, histologic and biologic markers, or hemodynamic data.

40 fferent high-risk groups, screening for both biologic markers provided better prognostic information

41 al response was correlated with amelioration biologic markers such as cytokine production (IFN-gamma,

42 We used a biologic marker, such as serum paraxanthine, a metabolit

43 Two small studies looking at biologic markers suggested that exercise may impact cyto

44 To date, there is no consensus on biologic markers that add value to these parameters.

45 aggressive lymphoma but clinically validated biologic markers that can predict natural history to tai

46 There are literally dozens of clinical and biologic markers that have been proposed as being predic

47 uantitative Western analysis, is a sensitive biologic marker to assess the short-term responsiveness

48 nfluence this variation and that addition of biologic markers to AJCC staging improves determination

49 suggesting a potential to develop surrogate biologic markers to identify the onset and progression o

50 Identification of biologic markers to predict clinical outcome and an enha

51 e were calculated for clinical variables and biologic markers using the Cox model for multivariate an

52 The model using these 3 biologic markers was highly predictive of overall surviv

53 injury occurs in scleroderma and provides a biologic marker whose relationship to disease activity a

54 The biologic marker with which to assess the efficacy of HER